Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1956 2
1957 2
1959 1
1960 1
1961 1
1962 2
1963 1
1964 2
1965 1
1966 2
1967 5
1968 6
1969 5
1970 8
1971 2
1972 3
1973 5
1974 6
1975 3
1976 10
1977 10
1978 4
1979 13
1980 13
1981 6
1982 13
1983 17
1984 15
1985 27
1986 12
1987 24
1988 46
1989 57
1990 35
1991 33
1992 44
1993 42
1994 31
1995 32
1996 44
1997 38
1998 48
1999 53
2000 55
2001 56
2002 55
2003 56
2004 58
2005 62
2006 71
2007 70
2008 84
2009 85
2010 84
2011 94
2012 135
2013 118
2014 154
2015 134
2016 160
2017 151
2018 132
2019 121
2020 164
2021 125
2022 108
2023 104
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

2,901 results

Results by year

Filters applied: . Clear all
Page 1
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, Shirasu H, Yamazaki K, Watanabe J, Kotaka M, Hirata K, Akazawa N, Kataoka K, Sharma S, Aushev VN, Aleshin A, Misumi T, Taniguchi H, Takemasa I, Kato T, Mori M, Yoshino T. Kotani D, et al. Among authors: taniguchi h. Nat Med. 2023 Jan;29(1):127-134. doi: 10.1038/s41591-022-02115-4. Epub 2023 Jan 16. Nat Med. 2023. PMID: 36646802 Free PMC article.
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T. Le DT, et al. Among authors: taniguchi h. J Clin Oncol. 2020 Jan 1;38(1):11-19. doi: 10.1200/JCO.19.02107. Epub 2019 Nov 14. J Clin Oncol. 2020. PMID: 31725351 Free PMC article. Clinical Trial.
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.
Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Hashiguchi Y, et al. Among authors: taniguchi h. Int J Clin Oncol. 2020 Jan;25(1):1-42. doi: 10.1007/s10147-019-01485-z. Epub 2019 Jun 15. Int J Clin Oncol. 2020. PMID: 31203527 Free PMC article.
Liver Cancer 2.0.
Taniguchi H. Taniguchi H. Int J Mol Sci. 2023 Dec 8;24(24):17275. doi: 10.3390/ijms242417275. Int J Mol Sci. 2023. PMID: 38139103 Free PMC article.
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
Taniguchi H, Caeser R, Chavan SS, Zhan YA, Chow A, Manoj P, Uddin F, Kitai H, Qu R, Hayatt O, Shah NS, Quintanal Villalonga Á, Allaj V, Nguyen EM, Chan J, Michel AO, Mukae H, de Stanchina E, Rudin CM, Sen T. Taniguchi H, et al. Cell Rep. 2022 May 17;39(7):110814. doi: 10.1016/j.celrep.2022.110814. Cell Rep. 2022. PMID: 35584676 Free PMC article.
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. Among authors: taniguchi h. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Sawada K, Taniguchi H, Fuse N, Nomura S, Fukui M, Matsuda S, Sakamoto Y, Uchigata H, Kitajima K, Kuramoto N, Asakawa T, Olsen S, Odegaard JI, Sato A, Fujii S, Ohtsu A, Yoshino T. Nakamura Y, et al. Among authors: taniguchi h. Nat Med. 2021 Nov;27(11):1899-1903. doi: 10.1038/s41591-021-01553-w. Epub 2021 Nov 11. Nat Med. 2021. PMID: 34764486 Free PMC article. Clinical Trial.
Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation.
Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Manoj P, Donoghue MTA, Won HH, Chan JM, Ciampricotti M, Chow A, Offin M, Chang JC, Ray-Kirton J, Tischfield SE, Egger J, Bhanot UK, Linkov I, Asher M, Sinha S, Silber J, Iacobuzio-Donahue CA, Roehrl MH, Hollmann TJ, Yu HA, Qiu J, de Stanchina E, Baine MK, Rekhtman N, Poirier JT, Loomis B, Koche RP, Rudin CM, Sen T. Quintanal-Villalonga A, et al. Among authors: taniguchi h. Cancer Discov. 2021 Dec 1;11(12):3028-3047. doi: 10.1158/2159-8290.CD-20-1863. Cancer Discov. 2021. PMID: 34155000 Free PMC article.
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsuhashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JI, Yoshino T. Nakamura Y, et al. Among authors: taniguchi h. Nat Med. 2020 Dec;26(12):1859-1864. doi: 10.1038/s41591-020-1063-5. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020649 Clinical Trial.
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy.
Quintanal-Villalonga A, Taniguchi H, Hao Y, Chow A, Zhan YA, Chavan SS, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Offin M, Ciampricotti M, Ray-Kirton J, Egger J, Bhanot U, Linkov I, Asher M, Roehrl MH, Qiu J, de Stanchina E, Hollmann TJ, Koche RP, Sen T, Poirier JT, Rudin CM. Quintanal-Villalonga A, et al. Among authors: taniguchi h. Cancer Res. 2022 Feb 1;82(3):472-483. doi: 10.1158/0008-5472.CAN-21-2964. Epub 2021 Nov 23. Cancer Res. 2022. PMID: 34815254 Free PMC article.
2,901 results